Remove 2002 Remove Clinical Trials Remove Patients Remove Terpenes
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History 119
article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

article thumbnail

Green Relief - Untitled Article

Green Relief

A 2014 study found that traumatic brain injury ( TBI ) patients who tested positive for THC were more likely to survive with less impairment than TBI patients who abstained from marijuana. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.